<DOC>
	<DOCNO>NCT00738205</DOCNO>
	<brief_summary>This international , multicenter study involve child treat Saizen® , growth hormone , train use easypod , new electronic injector complete questionnaire 12 week use . Both child naïve growth hormone dissatisfy current injection device recruit .</brief_summary>
	<brief_title>Evaluation Convenience Compliance Easypod™ Electronic Self-injector</brief_title>
	<detailed_description>An international , multicenter cross-sectional study ( Observatoire des pratiques médicales® ) involve cohort child treat Saizen® , growth hormone . The study require change usual medical management patient consider detrimental physical psychological integrity . No specific procedure examination request , protocol require particular treatment follow-up visit .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<criteria>Already treat patient dissatisfied current selfinjection device , naïve pediatric patient , case indication validate ( growth hormone deficiency , Turner 's syndrome , chronic renal failure , smallforgestational age [ SGA ] patient , base RCP ) Cases Saizen® contraindicate ( base local RCP ) Children return consultation , bring back Easypod™ electronic selfinjector . Children participate therapeutic trial , do 3month period precede recruitment observational study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Electronic device</keyword>
	<keyword>Growth hormone treatment</keyword>
</DOC>